Home Biosimilar Antibodies Others Others Cergutuzumab (Anti-CEACAM5 / CEA / CD66e)
For research use only. Not for use in humans.

Cergutuzumab (Anti-CEACAM5 / CEA / CD66e)

Synonyms: CD66e， CEA

Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanized monoclonal antibody which targets Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with immunostimulating and antineoplastic activities. MW : 146.48 KD.

Cergutuzumab (Anti-CEACAM5 / CEA / CD66e)

Quality Control

Batch: A284101 Purity: 99% Protein concentration: 9.11mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanized monoclonal antibody which targets Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with immunostimulating and antineoplastic activities. MW : 146.48 KD.
References

Product Details

CAS No. 1509916-03-3
Molecular Weight 146.48
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05658172 RECRUITING Breast Cancer Prof. Wolfgang Janni 2022-12-07
NCT07416552 RECRUITING Drug: SPLIT Abs|Drug: 203Pb-DOTAM|Drug: 212Pb-DOTAM Metastatic Colorectal Cancer Hoffmann-La Roche 2026-09-08 PHASE1
NCT07549412 RECRUITING Drug: Precemtabart tocentecan|Drug: Bevacizumab|Drug: Triflu Metastatic Colorectal Cancer EMD Serono Research & Development Institute, Inc. 2026-05-06 PHASE3
NCT06999382 RECRUITING Uptake of Systematic Review Evidence Deborah Salvo 2026-02-16
NCT07686445 NOT_YET_RECRUITING Drug: Intravenous AN4035|Drug: Intravenous AN4035 followed b Solid Tumor (Phase I); RAS Mutation; CEACAM5 Adlai Nortye Biopharma Co., Ltd. 2026-09-23 PHASE1
NCT07250386 RECRUITING NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 2025-10-13 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-05-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.